Released Feb 28, 2019, after the close
10-K filed Feb 28, 2019, 59 days after period end · 0001144204-19-011361
Q4 2018 · 10-K
Revenue$3.74M$3.74M +12.7% vs Q4 2017−12.9% vs Q3 2018
Net Income-$26.16M-$26.16M N/M vs Q4 2017N/M vs Q3 2018
EPS Diluted-$1.03-$1.03 N/M vs Q4 2017N/M vs Q3 2018
Operating Incomederived-$26,322,000N/M
Operating Cash Flowderived-$16,727,000N/M
Free Cash Flowderived-$16,938,000N/M
Margins · derived
Operating margin-704.7%−334.3 pt vs Q4 2017
Net margin-700.4%−609.7 pt vs Q4 2017
What the release said
The release
Same quarter
| Metric | Q4 2018 | Q4 2017 | Q4 2016 | Q4 2015 |
|---|---|---|---|---|
| Revenue | $3.74M | $3.32M | — | — |
| Net Income | -$26.16M | -$3.01M | -$11.55M | -$7.75M |
| EPS Diluted | -$1.03 | -$160.00 | -$0.67 | -$0.45 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR